Adaptive Biotechnologies (ADPT) News Today $8.24 -0.18 (-2.14%) Closing price 04:00 PM EasternExtended Trading$8.50 +0.26 (+3.14%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High - Here's WhyAdaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High - Here's What HappenedMarch 25 at 3:38 PM | marketbeat.comCharles Schwab Investment Management Inc. Acquires 39,831 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Charles Schwab Investment Management Inc. raised its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 4.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 956,574 shares of the company's stock after acquiring an additional 39March 25 at 3:18 AM | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Upgraded to Buy at The Goldman Sachs GroupMarch 24 at 2:29 AM | americanbankingnews.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up - Here's What HappenedAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up - Should You Buy?March 22, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Raised to "Buy" at The Goldman Sachs GroupThe Goldman Sachs Group upgraded shares of Adaptive Biotechnologies from a "neutral" rating to a "buy" rating and set a $9.00 target price on the stock in a report on Friday.March 22, 2025 | marketbeat.comGoldman Sachs Upgrades Adaptive Biotechnologies (ADPT)March 22, 2025 | msn.comAdaptive Biotechnologies upgraded to Buy from Neutral at Goldman SachsMarch 21, 2025 | markets.businessinsider.comAdaptive Biotechnologies (ADPT) was upgraded to a Buy Rating at Goldman SachsMarch 21, 2025 | markets.businessinsider.comAdaptive Biotech rises as Goldman Sachs upgrades on market dynamicsMarch 21, 2025 | msn.comAdaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In MarchMarch 21, 2025 | msn.comAdaptive Biotechnologies (NASDAQ:ADPT) Trading Up 6.9% - Should You Buy?Adaptive Biotechnologies (NASDAQ:ADPT) Trading 6.9% Higher - Still a Buy?March 20, 2025 | marketbeat.comAdaptive Biotechnologies (ADPT) Gets a Buy from BTIGMarch 18, 2025 | markets.businessinsider.comNikko Asset Management Americas Inc. Has $40.93 Million Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Nikko Asset Management Americas Inc. lessened its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 11.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,833,137 shares of the company's stock afterMarch 18, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Trading Down 6.1% After Insider SellingAdaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.1% Following Insider SellingMarch 14, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Director Sells $70,500.00 in StockAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) Director Peter M. Neupert sold 10,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $7.05, for a total transaction of $70,500.00. Following the transaction, the director now directly owns 224,690 shares in the company, valued at $1,584,064.50. The trade was a 4.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.March 13, 2025 | marketbeat.comInsider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) Director Sells $402,270.00 in StockAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) Director Robert Hershberg sold 53,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $7.59, for a total transaction of $402,270.00. Following the transaction, the director now owns 69,690 shares of the company's stock, valued at approximately $528,947.10. This represents a 43.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.March 13, 2025 | marketbeat.comPeter M. Neupert Sells 10,000 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) StockMarch 13, 2025 | insidertrades.comAdaptive Biotechnologies (NASDAQ:ADPT) Trading Up 10.4% - Time to Buy?Adaptive Biotechnologies (NASDAQ:ADPT) Trading 10.4% Higher - Still a Buy?March 12, 2025 | marketbeat.comAdaptive Biotechnologies launches assay enhancements for clonoSeqMarch 11, 2025 | markets.businessinsider.comAdaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell LymphomaMarch 11, 2025 | globenewswire.comUS Bancorp DE Sells 43,819 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)US Bancorp DE lowered its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 26.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 119,287 shares of the company's stock after selling 43,8March 11, 2025 | marketbeat.comEssex Investment Management Co. LLC Cuts Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Essex Investment Management Co. LLC reduced its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 12.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 625,838 shares of theMarch 10, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Down 6.5% After Insider SellingAdaptive Biotechnologies (NASDAQ:ADPT) Shares Down 6.5% Following Insider SellingMarch 8, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) CFO Sells $72,033.60 in StockAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CFO Kyle Piskel sold 10,320 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $6.98, for a total value of $72,033.60. Following the completion of the transaction, the chief financial officer now owns 269,010 shares in the company, valued at approximately $1,877,689.80. This trade represents a 3.69 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.March 7, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Director Michelle Renee Griffin Sells 15,664 SharesAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) Director Michelle Renee Griffin sold 15,664 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $7.94, for a total value of $124,372.16. Following the completion of the sale, the director now directly owns 51,685 shares in the company, valued at approximately $410,378.90. The trade was a 23.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.March 7, 2025 | marketbeat.comFrancis Lo Sells 20,875 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) StockAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) insider Francis Lo sold 20,875 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $6.99, for a total transaction of $145,916.25. Following the sale, the insider now directly owns 332,846 shares in the company, valued at approximately $2,326,593.54. The trade was a 5.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.March 7, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) COO Julie Rubinstein Sells 59,505 SharesAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 59,505 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $6.98, for a total transaction of $415,344.90. Following the completion of the transaction, the chief operating officer now directly owns 588,249 shares of the company's stock, valued at approximately $4,105,978.02. This represents a 9.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.March 7, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Sells $819,109.98 in StockAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 117,351 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $6.98, for a total value of $819,109.98. Following the transaction, the chief executive officer now directly owns 2,814,350 shares of the company's stock, valued at $19,644,163. The trade was a 4.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.March 7, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) CFO Kyle Piskel Sells 10,320 SharesMarch 7, 2025 | insidertrades.comPrincipal Financial Group Inc. Purchases Shares of 143,444 Adaptive Biotechnologies Co. (NASDAQ:ADPT)Principal Financial Group Inc. acquired a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 143,444 shares of the company's stock, valued at appMarch 7, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Down - Time to Sell?Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Down - What's Next?March 6, 2025 | marketbeat.comPrivate Advisor Group LLC Makes New $264,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Private Advisor Group LLC purchased a new stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 43,977 shares of the company's stock, valued at approximately $264,000. A number of other institutMarch 6, 2025 | marketbeat.comARK Investment Management LLC Sells 2,177,060 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)ARK Investment Management LLC reduced its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 18.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,424,074 shares of the company's stock after selling 2,177,060 sharesFebruary 26, 2025 | marketbeat.comChad M. Robins Sells 99,107 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) StockAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 99,107 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $8.44, for a total value of $836,463.08. Following the sale, the chief executive officer now owns 2,576,701 shares of the company's stock, valued at approximately $21,747,356.44. This represents a 3.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.February 22, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Chad M. Robins Sells 99,107 SharesFebruary 22, 2025 | insidertrades.comCathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive BiotechnologiesFebruary 22, 2025 | benzinga.comAdaptive Biotechnologies (NASDAQ:ADPT) Earns "Overweight" Rating from Piper SandlerPiper Sandler restated an "overweight" rating and issued a $11.00 price target (up from $7.00) on shares of Adaptive Biotechnologies in a research note on Thursday.February 21, 2025 | marketbeat.comAdaptive Biotechnologies price target raised to $11 from $7 at Piper SandlerFebruary 20, 2025 | markets.businessinsider.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Chad M. Robins Sells 158,921 SharesAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 158,921 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $8.46, for a total transaction of $1,344,471.66. Following the completion of the transaction, the chief executive officer now directly owns 2,576,701 shares in the company, valued at $21,798,890.46. This represents a 5.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 19, 2025 | marketbeat.comChad M. Robins Sells 211,160 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) StockAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 211,160 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $8.50, for a total value of $1,794,860.00. Following the completion of the transaction, the chief executive officer now owns 2,576,701 shares in the company, valued at approximately $21,901,958.50. This trade represents a 7.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.February 19, 2025 | marketbeat.comChad M. Robins Sells 158,921 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) StockFebruary 19, 2025 | insidertrades.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by DDD Partners LLCDDD Partners LLC lessened its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 91.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 64,747 shares of the company's stock afterFebruary 17, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.9% Following Analyst UpgradeAdaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.9% Following Analyst UpgradeFebruary 14, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High After Analyst UpgradeAdaptive Biotechnologies (NASDAQ:ADPT) Sets New 52-Week High Following Analyst UpgradeFebruary 14, 2025 | marketbeat.comADPT stock soars to 52-week high, reaching $8.33February 13, 2025 | msn.comScotiabank Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock PriceScotiabank increased their target price on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a research report on Thursday.February 13, 2025 | marketbeat.comAdaptive Biotechnologies price target raised to $12 from $10 at ScotiabankFebruary 13, 2025 | markets.businessinsider.comLegato Capital Management LLC Has $1.11 Million Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Legato Capital Management LLC cut its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 23.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 184,668 shares of the comFebruary 13, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)February 12, 2025 | markets.businessinsider.comAdaptive Biotechnologies Q4 revenue beats estimates, loss narrower than expectedFebruary 12, 2025 | msn.com Remove Ads Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address ADPT Media Mentions By Week ADPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADPT News Sentiment▼0.480.89▲Average Medical News Sentiment ADPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADPT Articles This Week▼144▲ADPT Articles Average Week Remove Ads Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADMA Biologics News Today PTC Therapeutics News Today Avidity Biosciences News Today Arcellx News Today Organon & Co. News Today Zai Lab News Today Ultragenyx Pharmaceutical News Today SpringWorks Therapeutics News Today Akero Therapeutics News Today Alvotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADPT) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADPT Stock Free ADPT Stock Alerts